Yalcinkaya, Y. Et Al. 2022. ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT. ANNALS OF THE RHEUMATIC DISEASES , vol.81 , 1499.

Yalcinkaya, Y., Amikishiyev, S., Aliyeva, N., Artim-Esen, B., Gul, A., Bingol, Z., ... Okumus, G.(2022). ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT. ANNALS OF THE RHEUMATIC DISEASES , vol.81, 1499.

Yalcinkaya, Yasemin Et Al. "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT," ANNALS OF THE RHEUMATIC DISEASES , vol.81, 1499, 2022

Yalcinkaya, Yasemin Et Al. "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT." ANNALS OF THE RHEUMATIC DISEASES , vol.81, pp.1499, 2022

Yalcinkaya, Y. Et Al. (2022) . "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT." ANNALS OF THE RHEUMATIC DISEASES , vol.81, p.1499.

@article{article, author={Yasemin YALÇINKAYA Et Al. }, title={ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-IAH PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT}, journal={ANNALS OF THE RHEUMATIC DISEASES}, year=2022, pages={1499} }